Bayer and Evotec recently formed a partnership to create multiple clinical candidate treatments for kidney diseases, such as chronic kidney disease in diabetes patients, for the next five years.
The multi-target research partnership requires both of the companies to develop new drug targets. They will create a comprehensive set of high-quality technology platforms that will unite the creation process for the innovative treatment options.
“Chronic kidney disease is a severe medical condition with insufficient treatment options for many patients,” Andreas Busch, member of the executive committee of Bayer AG's Pharmaceuticals Division and head of drug discovery, said. “This new research alliance with Evotec will perfectly complement Bayer's current research activities in this area of high unmet medical need. Evotec is already a strong partner of ours, and we look forward to continuing the relationship to develop novel drug candidates for the benefit of patients.”
Throughout the preclinical development of these treatments, the partners have agreed to share their responsibilities.
“This research alliance will particularly target chronic kidney diseases, which are the leading cause of end-stage renal disease,” Dr. Cord Dohrmann, chief scientific officer at Evotec, said. “Currently, patients with end-stage renal disease face dialysis or kidney transplantation as the only available treatment options. There are no effective treatments that can significantly slow or reverse disease progression. We are very proud and excited to expand our efforts in kidney diseases together with Bayer in this area of enormous unmet medical need.”
